Lv72
3340 积分 2023-01-17 加入
Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial
1个月前
已完结
Recent Advances in Peptide Linkers of Antibody–Drug Conjugates
1个月前
已完结
Small Molecule–Degrader Conjugates: Evaluating the Structure–Activity Relationship of Linkers to Overcome In Vivo Barriers in PROTAC Delivery
1个月前
已完结
Discovery and Characterization of RP04340 : A Highly Potent and Orally Active Pan-KRAS PROTAC Degrader
1个月前
已完结
Lead Optimization of Multimutant KRAS Switch-II Pocket Macrocyclic Inhibitors via Isosteric Replacement to Improve ADME and Oral Exposure
1个月前
已完结
Discovery of Imidazo[1,2-b]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitors
2个月前
已完结
Design, Synthesis, and Biological Evaluation of Pyrrolo[1,2-a]quinoxalin-4(5H)-one Derivatives as Potent and Orally Available Noncovalent Bruton’s Tyrosine Kinase (BTK) Inhibitors
2个月前
已完结
Strategic Use of Benzylic Alcohols Reveals Cryptic Hydrogen-Bonding Interactions: Discovery of HBC-12551 as a Potent Noncovalent Bruton’s Tyrosine Kinase Inhibitor
2个月前
已完结
Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
2个月前
已完结
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer Therapy
3个月前
已完结
皖公网安备34019202002308
